Featured Research

from universities, journals, and other organizations

Taurine: Key To The Visual Toxicity Of An Anti-epileptic Drug For Children?

Date:
February 17, 2009
Source:
INSERM (Institut national de la santé et de la recherche médicale)
Summary:
Vigabatrin, first intention molecule for the treatment of epilepsy in children, in many cases produces secondary effects that lead to an irreversible loss of vision. Medical researchers have just discovered the origin of this secondary effect and have proposed strategies for limiting it.

Vigabatrin (Sabril), first intention molecule for the treatment of epilepsy in children, in many cases produces secondary effects that lead to an irreversible loss of vision. Serge Picaud, head of research at Inserm, and his colleagues of the Institut de la Vision have just discovered the origin of this secondary effect and have proposed strategies for limiting it.

Related Articles


They have shown that vigabatrin provokes a marked decrease in the blood level in an amino acid, taurine, resulting in a degeneration of the retina cells induced by light. The researchers therefore suggest that exposure to light should be reduced and a taurine-rich diet introduced in order to curb immediately these secondary effects in children undergoing treatment. As for the validation of an alternative treatment associating vigabatrin and taurine, this will necessitate several years of development.

This work is published in the review Annals of Neurology.

Epilepsy affects 1% of the world's population. With children, its treatment remains extremely restricted, and vigabatrin, (marketed in France under the name of Sabril®), has obtained marketing authorisation for children aged under 2 years. This anticonvulsant, which is also administered to adults in the case of failure of other treatments, is at the same time now being evaluated for the treatment of addiction to heroin, cocaine and methamphetamines.

However, the serious secondary effects of this drug can induce an impairment of the retina and a restriction of the visual field, noted, depending on the studies, in 10% to 40% of patients.

In order to reach an understanding of this drug's modes of actions, and in particular the mechanism of visual function impairment, the Inserm researchers first of all administered vigabatrin to rats over a period of several months and analysed the influence of exposure to light during the treatment. The results show that there is no damage to the retina when the animals are kept in the dark throughout the treatment.

Moreover, since previous work had shown that a deficiency of the organism in taurine (amino acid) triggers the degeneration of the photoreceptors (cells of the retina converting light into nervous signals), the researchers measured, in rodents, the plasma level of 19 amino acids. Whereas the concentration was identical for most of the amino acids in animals under vigabatrin and in non-treated rats, the taurine level turned out to be 67% lower in treated animals

Taurine is essentially contributed by diet. By providing certain of the animals under treatment with a taurine supplementation, the researchers noted that their visual acuity was greater than that of the animals without supplementation. In addition, the amino acid doses administered to six children subject to regular attacks of epilepsy and treated under vigabatrin reveal a taurine level that is far below the normal values reported for children of the same age – and in some cases even undetectable.

On the strength of these various tests, the scientists were able to prove that vigabatrin induces a pronounced reduction of the taurine level in the plasma. This marked fall is responsible for the degeneration of the photoreceptors and thus for the retinal toxicity in the animals exposed to light.

Pending confirmation in the human of the interest of providing patients under vigabatrin with a taurine supplementation, the researchers propose immediate solutions designed to limit the secondary effects in these patients. "In the first instance, care should therefore be taken to ensure that patients under vigabatrin consume a sufficient amount of food containing taurine. It is also important that they should be exposed to as little light as possible (e.g.; no night lights in a baby's bedroom at night) and should be induced to wear sunglasses", says Serge Picaud.

The researchers also emphasize that any taurine supplementation must be subject to medical advice.


Story Source:

The above story is based on materials provided by INSERM (Institut national de la santé et de la recherche médicale). Note: Materials may be edited for content and length.


Cite This Page:

INSERM (Institut national de la santé et de la recherche médicale). "Taurine: Key To The Visual Toxicity Of An Anti-epileptic Drug For Children?." ScienceDaily. ScienceDaily, 17 February 2009. <www.sciencedaily.com/releases/2009/02/090217112124.htm>.
INSERM (Institut national de la santé et de la recherche médicale). (2009, February 17). Taurine: Key To The Visual Toxicity Of An Anti-epileptic Drug For Children?. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/02/090217112124.htm
INSERM (Institut national de la santé et de la recherche médicale). "Taurine: Key To The Visual Toxicity Of An Anti-epileptic Drug For Children?." ScienceDaily. www.sciencedaily.com/releases/2009/02/090217112124.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins